Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
146745
¥ thousandWording
Avoiding a definitive answer
How definitive the wording is.Results for this period
Third quarter1 January 2026–30 September 2026Non-consolidated (individual)Japanese GAAPNet Sales55¥ millionYear on year -15.7%Progress 78.6%
Operating profit-369¥ million
Ordinary income-364¥ million
Net income attributable to owners of the parent-513¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share−¥79.20
Financial position at period-end
Total assets1,366¥ million
of which net assets 1,270 ¥ millionEquity ratio 93.0%vs. prior year-end -1.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥70 million (YoY -22.5%)
Operating profit¥-515 million
Ordinary income¥-509 million
Net income¥-700 million
Revision to Earnings ForecastNot disclosed → Net Sales ¥70 million / Operating profit ¥-515 million / Ordinary income ¥-509 million / Net income ¥-700 million
Annual Dividend Forecast¥0 → ¥0
Factors Behind Changes in Business Performance
Business revenue was ¥55.6 million, primarily from research grants and other sources. The revision to the full-year forecast reflects the loss of milestone income following a change in the joint drug discovery research plan due to circumstances on the partner company's side, as well as impairment charges on building improvements and tools, fixtures and equipment.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsOn 29 October 2026, the issuance and payment for the 5th through 9th series of stock acquisition rights by way of a third-party allotment were completed. The total number of potential shares is 3.6 million, and the funds raised would be approximately ¥1.773 billion if all the rights are exercised. The funds are scheduled to be allocated to research and development expenses for the company's pipeline from January 2027 through December 2029.
Impairment loss¥146,745 thousand
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥146,745 thousand
Depreciation and amortization¥2,457 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo
Issued Shares at Period-End6,487,114 shares
Treasury Shares at Period-End— shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥55 million (YoY -15.7%) |
| Operating profit | ¥-369 million |
| Ordinary income | ¥-364 million |
| Profit attributable to owners of the parent | ¥-513 million |
| Net income per share | −¥79.20 |
| Equity ratio | End of the current fiscal period 93 / End of previous period 94.6 |
| Total assets | ¥1,366 million |
| Net assets | ¥1,270 million |
| Full-year earnings forecast | Net Sales ¥70 million (YoY -22.5%) / Operating profit ¥-515 million / Ordinary income ¥-509 million / Net income ¥-700 million |
| Revision to Earnings Forecast | Not disclosed → Net Sales ¥70 million / Operating profit ¥-515 million / Ordinary income ¥-509 million / Net income ¥-700 million |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Depreciation and amortization | ¥2,457 thousand |
| Impairment loss | ¥146,745 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥146,745 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | On 29 October 2026, the issuance and payment for the 5th through 9th series of stock acquisition rights by way of a third-party allotment were completed. The total number of potential shares is 3.6 million, and the funds raised would be approximately ¥1.773 billion if all the rights are exercised. The funds are scheduled to be allocated to research and development expenses for the company's pipeline from January 2027 through December 2029. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 6,487,114 shares |
| Treasury Shares at Period-End | — shares |
| Factors Behind Changes in Business Performance | Business revenue was ¥55.6 million, primarily from research grants and other sources. The revision to the full-year forecast reflects the loss of milestone income following a change in the joint drug discovery research plan due to circumstances on the partner company's side, as well as impairment charges on building improvements and tools, fixtures and equipment. |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogChanges in the scope of consolidation
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The research plan for the joint drug discovery research was changed due to circumstances on the partner company's side, making the originally anticipated milestone income no longer expected, and impairment charges were recognized on building improvements and tools, fixtures and equipment placed into use in fiscal 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.